ISS urges Pacira holders to back management slate, reject DOMA push to sell company at June 9 meeting

Pacira BioSciences

Pacira BioSciences

PCRX

0.00
  • ISS urged shareholders to back management’s three director nominees at the June 9, 2026 annual meeting.
  • ISS recommended voting against the three nominees put forward by activist DOMA Perpetual Capital Management.
  • ISS cited improved performance since the 5x30 strategy launch, board refreshment, governance changes, and limited experience on the dissident slate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606011650PR_NEWS_USPR_____SF73136) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.